Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16313237 | 0.81 | RAB9A (0.40) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL14943751 | 0.78 | RAB9A (0.35) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL463976 | 0.78 | METAP1 (0.45) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL13274393 | 0.78 | METAP1 (0.45) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL840614 | 0.78 | METAP1 (0.45) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL13049846 | 0.77 | KMT2A (0.39) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| Hydrochloric Acid SCHEMBL27922164 | 0.77 | METAP1 (0.44) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| Hydrochloric Acid SCHEMBL27922161 | 0.77 | METAP1 (0.44) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL15623642 | 0.75 | METAP1 (0.58) | RAB9ASMN1; SMN2GAAMAPTMETAP1 | |
| SCHEMBL904231 | 0.75 | METAP1 (0.58) | RAB9ASMN1; SMN2GAAMAPTMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |